Entero Healthcare Solutions Limited has informed the Exchange about Investor Presentation
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare filed its Q3FY26 investor presentation on February 12, 2026. Q3 revenue grew 25.6% YoY to Rs. 1,706.5 Cr (9MFY26: Rs. 4,681.3 Cr, +24.6%), with organic like-for-like growth at a healthy 17.1% in the quarter. EBITDA rose 35.5% YoY to Rs. 67.8 Cr with margin expanding 29bps to 4.0%, and PAT margin was 2.0% (2.3% excluding a one-off Rs. 6.1 Cr New Labour Code impact). Operating cashflow turned strongly positive at Rs. 49 Cr in Q3, a big swing from negative cashflows in prior quarters. The company closed 7 acquisitions YTD, with emphasis on the MedTech segment, and reiterated that proforma acquisitions will add 50-75bps to EBITDA margin and 70-90bps to gross margin. MedTech revenue is expected to cross Rs. 1,000 Cr in the next financial year.
Positive for shareholders — improving margins, strong cashflow generation, and acquisition-driven growth signal operational momentum. Management's explicit guidance on near-term margin expansion could support stock sentiment, though margins remain thin at 4% EBITDA.